Clinical trials
Lung Cancer Stage I clinical trials
Below are recruiting lung cancer stage i clinical trials, each written for real people, not researchers. We’re tracking 1,145 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07045103Recruiting
New imaging tool for faster lung cancer detection during bronchoscopy
This trial is testing a new imaging technology that uses artificial intelligence to help doctors quickly identify lung cancer during a standard bronchoscopy procedure. If you are scheduled for a lung biopsy to check for cancer, this study may help improve detection speed and accuracy.
San Diego, CaliforniaAges 22 years+ - NCT06361589Recruiting
Lorlatinib for advanced ALK-positive lung cancer
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
Chengdu, SichuanAges 18 years+ - NCT05934032Recruiting
Genomic medicine for non-surgical lung cancer
This trial is part of a lung cancer network that uses genetic (DNA) testing to better understand and treat non-surgical lung cancer. You might be eligible if you have certain stages of non-small cell lung cancer and can consent to participate.
CologneAges 18 years+ - NCT06667908RecruitingPhase 2
Study of a drug with chemoradiation for stage 3 lung cancer
This trial tests a new drug, JNJ-90301900, given together with standard chemotherapy and radiation, followed by maintenance immunotherapy (durvalumab) for people with stage 3 non-small cell lung cancer that cannot be surgically removed. The goal is to see if adding this drug improves outcomes.
La Jolla, CaliforniaAges 18 years+ - NCT07398599Recruiting
Double-dose targeted therapy plus chemo for lung cancer spread to brain lining
This trial tests a stronger dose of an EGFR-targeted drug combined with bevacizumab and chemotherapy into the spinal fluid for patients with non-small cell lung cancer that has spread to the lining of the brain and is no longer responding to standard treatment.
Nanchang, JiangxiAges 18–99 - NCT07399210Recruiting
Detecting lung nodule cancer with a blood test
This study aims to see if a blood test can tell if a lung nodule is cancerous or not. It may help doctors avoid unnecessary procedures.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06945484Recruiting
Exercise program for lung cancer before surgery
This trial tests whether a personalized exercise plan can help people with lung cancer who are getting chemotherapy or immunotherapy before surgery. You’ll be asked to follow an exercise routine during your treatment.
Galveston, TexasAges 18 years+ - NCT06674538Enrolling by invitationPhase 1
Antibody trial for advanced solid tumors
This trial tests an antibody treatment for people with stage IV cancer that has not responded to previous treatment. It aims to find a new option for patients with several types of advanced solid tumors.
Hershey, PennsylvaniaAges 18 years+ - NCT03375983RecruitingPhase 1/Phase 2
Immune treatment with malaria cells for advanced solid cancers
This early-phase study tests a “malaria-based” immune treatment to help the immune system fight advanced cancers. It’s designed for people whose cancer can be measured on scans and whose organs and blood counts are strong enough for immunotherapy.
Guangzhou, GuangdongAges 18–70 - NCT05376878RecruitingPhase 4
PET/MRI scan to guide treatment in HER2+ brain metastatic breast cancer
This trial tests a special PET/MRI imaging scan using a labeled drug to help doctors evaluate HER2+ breast cancer that has spread to the brain. It focuses on patients who plan to receive fam-trastuzumab deruxtecan, a targeted cancer medicine, and aims to see how well the scan can support treatment decisions.
Duarte, CaliforniaAges 18 years+ - NCT06269211RecruitingPhase 2
Immunotherapy before surgery for EGFR-mutated lung cancer
This trial tests whether giving an immunotherapy drug (toripalimab) before surgery can help people with a specific type of lung cancer (EGFR-mutated, PD-L1 positive) that can be removed. The goal is to see if it improves treatment results compared to surgery alone.
Guangzhou, GuangdongAges 18 years+ - NCT07085182RecruitingPhase 2
Tislelizumab plus radiation for advanced lung cancer
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
Zibo, ShandongAges 18–75 - NCT06379087RecruitingPhase 2
Radiation, immunotherapy and targeted therapy for early-stage lung cancer
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
Hangzhou, ZhejiangAges 18–75 - NCT06607796RecruitingPhase 3
PTS injection for stage 4 lung cancer without gene mutations
This trial tests injecting a drug called PTS directly into lung tumors for people with stage 4 non-small cell lung cancer that doesn't have certain gene changes. It is for patients whose tumors have stayed stable after first-line treatment and are located in a small area of the outer lung.
Guangzhou, GuangdongAges 18–75 - NCT06951464RecruitingPhase 2
Targeted therapy before surgery for EGFR-mutated lung cancer
This trial tests a combination of two targeted drugs (BL-B01D1 and almonertinib) given before surgery to shrink EGFR-mutated lung cancer. The goal is to make surgery more effective and possibly improve long-term outcomes.
Chengdu, SichuanAges 18–75 - NCT07295821RecruitingPhase 2
Osimertinib for stage III lung cancer patients who can't have chemo
This trial tests a targeted therapy pill (osimertinib) combined with radiation for people with a specific type of stage III lung cancer (EGFR mutation-positive) who cannot receive chemotherapy. The goal is to see if this treatment can shrink or control the cancer.
BeijingAges 18 years+ - NCT06745908RecruitingPhase 3
New drug combo for lung cancer after immunotherapy stops working
This trial tests a new drug combination (N-803 and tislelizumab with chemotherapy) for people whose lung cancer stopped responding to standard immunotherapy. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
Springdale, ArkansasAges 18–90 - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT06192849RecruitingPhase 2
Furmonertinib after surgery for EGFR 20 insertion lung cancer
This trial tests a targeted pill (furmonertinib) to prevent your lung cancer from coming back after surgery. It is for people with a certain genetic change in their tumor (EGFR exon 20 insertion) and stage IB, II, or IIIA disease.
Chengdu, SichuanAges 18 years+ - NCT06222489RecruitingPhase 2
HER3 PET scan for advanced EGFR-mutant lung cancer
This study uses a special PET/CT scan to measure a protein called HER3 in your tumors. The scan uses a radioactive version of the drug patritumab deruxtecan (HER3-DXd). This test may help doctors understand how much HER3 is in your cancer and decide if HER3-targeted therapy could work for you.
Amsterdam, North HollandAges 18 years+ - NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
La Jolla, CaliforniaAges 18 years+ - NCT04944563Recruiting
Segmentectomy vs lobectomy for small middle-lung lung cancer
This trial compares two types of lung surgery for certain small lung cancers in the middle part of the lung: removing a segment (segmentectomy) versus removing a whole lobe (lobectomy). It aims to see which surgery works better while balancing cancer control and lung function.
Nanjing, JiangsuAges 18–75 - NCT05613413RecruitingPhase 2
Maintenance cabozantinib plus pembrolizumab after lung cancer control
This trial tests whether continuing treatment with cabozantinib plus pembrolizumab after your metastatic squamous lung cancer responds (or is stable) can help people live longer and stay in control. It may be an option if your cancer has already shown it can respond to initial (first-line) treatment.
Chicago, IllinoisAges 18 years+ - NCT06043973RecruitingPhase 3
Almonertinib plus anlotinib for first-line advanced lung cancer
This trial tests a combination of two targeted drugs (almonertinib and anlotinib) as first treatment for advanced non-small cell lung cancer that has specific gene changes (EGFR and TP53 mutations). The goal is to see if the pair works better than standard care.
Jinan, ShandongAges 18–75
Hear when a new Lung Cancer Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer stage i?
- Yes. Clin2 currently lists 1,145 recruiting lung cancer stage i studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer stage i trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer stage i trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.